期刊
CELL
卷 184, 期 5, 页码 1171-+出版社
CELL PRESS
DOI: 10.1016/j.cell.2021.01.037
关键词
-
资金
- DOE Office of Science User Facility [DE-AC02-05CH11231]
- ALS-ENABLE program - NIH, National Institute of General Medical Sciences [P30 GM124169-01]
- NHS
- FAH Project [17311]
- Medical Research Council (MRC) [MC UU 1201412]
- Wellcome Trust [206298/Z/17/Z]
- Chief Scientist Office [COV/EDI/20/11]
- MRC part of UK Research & Innovation (UKRI)
- NIH Research (NIHR)
- Genome Research Limited
- NIHR [CO-CIN-01, 201385]
- MRC [MC_PC_ 19059]
- NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool
- Public Health England (PHE)
- Liverpool School of Tropical Medicine
- University of Oxford [200907]
- NIHR HPRU in Respiratory Infections at Imperial College London with PHE [200927]
- Wellcome Trust and Department for International Development (DID) [215091/Z/18/Z]
- Bill and Melinda Gates Foundation [OPP1209135]
- Liverpool Experimental Cancer Medicine Centre [C18616/A25153]
- NIHR Biomedical Research Centre at Imperial College London [IS-BRC-1215-20013]
- EU Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) [602525]
- NIH [P30 CA008748, R01 GM121505, R01 GM132386]
- NSF [CHI-1904822]
- Sloan Kettering Institute
- Henry Krenter Foundation
- Helmut Horten Foundation
- Tri-Institutional PhD Program in Computational Biology and Medicine
- Vir Biotechnology
- Molecular Sciences Software Institute
- Bayer
- Randy Read's Wellcome Trust [209407/Z/17/Z]
- Wellcome Trust [209407/Z/17/Z] Funding Source: Wellcome Trust
- MRC [MC_UU_12014/10, MC_PC_19027] Funding Source: UKRI
- UKRI [MR/S032304/1] Funding Source: UKRI
- Chief Scientist Office [COV/EDI/20/11] Funding Source: researchfish
SARS-CoV-2 virus can mutate and evade immunity, with mutations like N439K conferring resistance against neutralizing monoclonal antibodies and enhancing binding affinity to hACE2 receptor. Despite similar in vitro replication fitness and clinical outcomes compared to wild type, N439K mutation highlights the importance of ongoing molecular surveillance for guiding vaccine and therapeutic development and usage.
SARS-CoV-2 canmutate and evade immunity, with consequences for efficacy of emerging vaccines and antibody therapeutics. Here, we demonstrate that the immunodominant SARS-CoV-2 spike (S) receptor binding motif (RBM) is a highly variable region of S and provide epidemiological, clinical, and molecular characterization of a prevalent, sentinel RBM mutation, N439K. We demonstrate N439K S protein has enhanced binding affinity to the hACE2 receptor, and N439K viruses have similar in vitro replication fitness and cause infections with similar clinical outcomes as compared to wild type. We show the N439K mutation confers resistance against several neutralizing monoclonal antibodies, including one authorized for emergency use by the US Food and Drug Administration (FDA), and reduces the activity of some polyclonal sera from persons recovered from infection. Immune evasion mutations that maintain virulence and fitness such as N439K can emerge within SARS-CoV-2 S, highlighting the need for ongoing molecular surveillance to guide development and usage of vaccines and therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据